- NOX66 to extend reach from potentiating chemotherapy to potentiating radiotherapy
- Guidance to market on major program initiative.
As foreshadowed in the Company’s recent Prospectus, the Company post-IPO intended to expand its clinical pipeline and clinical assets.
Noxopharm today announced that it has initiated a major research program testing the ability of NOX66 to promote the anti-cancer effects of radiotherapy. The program will involve clinical trials in Australia and overseas.
For further information please download PDF attached:
Download this document
